Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.

Airi Hamano, Sumito Shingaki, Y. Abe, Kanji Miyazaki, Rieko Sekine, Yasunori Nakagawa, Nobuhiro Tsukada, Yutaka Hattori, Kenshi Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple myeloma (MM). However, whether long-term treatment using NAs may increase the risk of second primary malignancies is a concern. Three hundred and thirty-three patients with MM were treated at our hospital from 1998 to 2013. Additional chromosomal abnormalities (CAs), associated with secondary myelodysplastic syndrome/acute myeloid leukemia, were observed in 13 of 152 users of NAs, but in 38 of 181 non-users of NAs. The cumulative CA incidence was higher in non-users of NAs. The CAs frequently observed were 13q-, 20q-, +8 in users of NAs, while -5/5q- and -7/7q- were detected in non-users of NAs. The total dose and treatment period of NAs did not differ between CAs-positive and -negative patients. However, a higher dose of melphalan was observed to have been used in patients who had CAs. Longer follow-up periods are necessary for an accurate risk assessment.

Original languageEnglish
Pages (from-to)428-435
Number of pages8
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume55
Issue number4
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Multiple Myeloma
Acute Myeloid Leukemia
Chromosome Aberrations
Melphalan
Thalidomide
Second Primary Neoplasms
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. / Hamano, Airi; Shingaki, Sumito; Abe, Y.; Miyazaki, Kanji; Sekine, Rieko; Nakagawa, Yasunori; Tsukada, Nobuhiro; Hattori, Yutaka; Suzuki, Kenshi.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 55, No. 4, 2014, p. 428-435.

Research output: Contribution to journalArticle

Hamano, A, Shingaki, S, Abe, Y, Miyazaki, K, Sekine, R, Nakagawa, Y, Tsukada, N, Hattori, Y & Suzuki, K 2014, 'Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 55, no. 4, pp. 428-435.
Hamano, Airi ; Shingaki, Sumito ; Abe, Y. ; Miyazaki, Kanji ; Sekine, Rieko ; Nakagawa, Yasunori ; Tsukada, Nobuhiro ; Hattori, Yutaka ; Suzuki, Kenshi. / Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2014 ; Vol. 55, No. 4. pp. 428-435.
@article{057d95681518481a91e6d59709c8ca41,
title = "Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.",
abstract = "The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple myeloma (MM). However, whether long-term treatment using NAs may increase the risk of second primary malignancies is a concern. Three hundred and thirty-three patients with MM were treated at our hospital from 1998 to 2013. Additional chromosomal abnormalities (CAs), associated with secondary myelodysplastic syndrome/acute myeloid leukemia, were observed in 13 of 152 users of NAs, but in 38 of 181 non-users of NAs. The cumulative CA incidence was higher in non-users of NAs. The CAs frequently observed were 13q-, 20q-, +8 in users of NAs, while -5/5q- and -7/7q- were detected in non-users of NAs. The total dose and treatment period of NAs did not differ between CAs-positive and -negative patients. However, a higher dose of melphalan was observed to have been used in patients who had CAs. Longer follow-up periods are necessary for an accurate risk assessment.",
author = "Airi Hamano and Sumito Shingaki and Y. Abe and Kanji Miyazaki and Rieko Sekine and Yasunori Nakagawa and Nobuhiro Tsukada and Yutaka Hattori and Kenshi Suzuki",
year = "2014",
language = "English",
volume = "55",
pages = "428--435",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "4",

}

TY - JOUR

T1 - Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.

AU - Hamano, Airi

AU - Shingaki, Sumito

AU - Abe, Y.

AU - Miyazaki, Kanji

AU - Sekine, Rieko

AU - Nakagawa, Yasunori

AU - Tsukada, Nobuhiro

AU - Hattori, Yutaka

AU - Suzuki, Kenshi

PY - 2014

Y1 - 2014

N2 - The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple myeloma (MM). However, whether long-term treatment using NAs may increase the risk of second primary malignancies is a concern. Three hundred and thirty-three patients with MM were treated at our hospital from 1998 to 2013. Additional chromosomal abnormalities (CAs), associated with secondary myelodysplastic syndrome/acute myeloid leukemia, were observed in 13 of 152 users of NAs, but in 38 of 181 non-users of NAs. The cumulative CA incidence was higher in non-users of NAs. The CAs frequently observed were 13q-, 20q-, +8 in users of NAs, while -5/5q- and -7/7q- were detected in non-users of NAs. The total dose and treatment period of NAs did not differ between CAs-positive and -negative patients. However, a higher dose of melphalan was observed to have been used in patients who had CAs. Longer follow-up periods are necessary for an accurate risk assessment.

AB - The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple myeloma (MM). However, whether long-term treatment using NAs may increase the risk of second primary malignancies is a concern. Three hundred and thirty-three patients with MM were treated at our hospital from 1998 to 2013. Additional chromosomal abnormalities (CAs), associated with secondary myelodysplastic syndrome/acute myeloid leukemia, were observed in 13 of 152 users of NAs, but in 38 of 181 non-users of NAs. The cumulative CA incidence was higher in non-users of NAs. The CAs frequently observed were 13q-, 20q-, +8 in users of NAs, while -5/5q- and -7/7q- were detected in non-users of NAs. The total dose and treatment period of NAs did not differ between CAs-positive and -negative patients. However, a higher dose of melphalan was observed to have been used in patients who had CAs. Longer follow-up periods are necessary for an accurate risk assessment.

UR - http://www.scopus.com/inward/record.url?scp=84906096711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906096711&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 428

EP - 435

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 4

ER -